Category: Consultation

Consultations: CRG actions and draft shared care protocol

April 13, 2022

Two new consultations have been opened on the GMMMG consultations page. 

CRG actions

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the April 2022 CRG meeting. Actions in this consultation include:

  • Simple eye ointment – DNP
  • Goserelin and leuprorelin for male early or advanced breast cancer – AMBER (see also consultation on updated draft shared care protocol)
  • Empagliflozin for chronic heart failure – GREEN following specialist advice
  • Dapagliflozin for chronic kidney disease – GREEN
  • Phenazone/lidocaine eardrops – add to formulary for treatment of otitis media
  • Pitolisant for excessive daytime sleepiness caused by obstructive sleep apnoea – DNP
  • Solriamfetol for excessive daytime sleepiness caused by obstructive sleep apnoea – DNP
  • Pegcetacoplan for paroxysmal nocturnal haemoglobinuria – RED
  • Atidarsagene autotemcel for metachromatic leukodystrophy – RED

Shared care protocol: GnRH analogues for breast cancer

CRG seek comments on this updated shared care protocol for the treatment of breast cancer.

The main changes are:

  • The addition of leuprorelin within the indications listed in the SCP
  • The SCP now includes the treatment of male breast cancer within the indications detailed in the SCP
  • A move to the new approved GM shared care protocol format.

Both consultations will run until 5pm on Wednesday 25th May 2022. Comments can be submitted using the feedback forms on the GMMMG consultations page, and comments are invited from all stakeholders.

Consultation: inclisiran information for primary care prescribers

March 22, 2022

A new consultation has been opened on the GMMMG consultations page on a draft information leaflet for inclisiran. 

The draft provides additional advice and information for prescribers, and is intended to support primary care prescribers and ensure a quality standard for the prescribing of inclisiran.

The consultation will be open until 5pm on Tuesday 3rd May 2022, and comments are invited from all stakeholders.

Consultation: actions from March meeting of CRG

March 10, 2022

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the March 2022 CRG meeting.

Actions in this consultation include:

  • Moxonidine – GREEN following specialist initiation
  • Ponesimod for relapsing-remitting multiple sclerosis – RED
  • Upadacitinib for active psoriatic arthritis – RED
  • Palforzia for peanut allergy in children and young people – RED on the paediatric RAG list, and GREY and RED on the adult RAG list, only for use in people aged 18 and over if treatment is started between the ages of 4 and 17, as per NICE guidance
  • Odevixibat for progressive familial intrahepatic cholestasis – RED

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Thursday 21st April 2022.

Consultation: actions from February meeting of CRG

February 21, 2022

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the February 2022 CRG meeting.

Actions in this consultation include:

  • Modafinil for narcolepsy and in Parkinson’s disease: GREEN following specialist initiation
  • Dacepton (apomorphine): AMBER; to be added to existing shared care protocol
  • Bempedoic acid: GREEN following specialist advice (previously specialist initiation)
  • Sotrovimab for COVID-19: RED
  • Mexiletine for myotonia: RED
  • Liraglutide for obesity in people aged 12-17: Do Not Prescribe
  • Dupilumab for severe asthma: RED
  • Belimumab for SLE: RED
  • Cenobamate for epilepsy: GREEN following specialist initiation (by a tertiary epilepsy service)
  • Risdiplam for spinal muscular atrophy: RED
  • Solriamfetol for narcolepsy: RED
  • Fostamatinib for chronic ITP: Do Not Prescribe

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Monday 4th April 2022.

New consultations: high cost drugs pathways

February 10, 2022

Two new consultations have been opened on the GMMMG consultations page. The topics are:

  • High cost drugs pathway: psoriatic arthritis
  • High cost drugs pathway: axial spondyloarthritis

These consultations will be open until 5pm on Thursday 22nd March 2022, and comments are invited from all stakeholders.

GMMMG are mindful of additional service pressures at present therefore if you foresee any problems giving input on these consultations, or if you have any questions, please contact the secretariat at nuth.enquires.gmmmg@nhs.net.

New consultations: pathway updates and formulary amendments

December 20, 2021

A batch of new consultations has been opened on the GMMMG consultations page. The topics include:

  • Actions from the December meeting of CRG
  • Updated rheumatoid arthritis high cost drugs pathway
  • Updated neuropathic pain pathway
  • Updated headache pathway
  • Updated primary care rebate scheme ethical framework

Each of these consultations will be open until 5pm on Monday 14th February, and comments are invited from all stakeholders.

GMMMG are mindful of additional service pressures at present, therefore these consultations will run for eight weeks instead of the usual six. Every effort has been made to allow sufficient time for appropriate clinical input to these documents, but if you foresee any problems or have any questions please contact the secretariat at nuth.enquires.gmmmg@nhs.net.

Consultation: actions from November meeting of CRG

November 11, 2021

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the November 2021 CRG meeting.

Actions in this consultation include:

  • Insulin aspart Sanofi (Trurapi) to be added to formulary as a GREEN drug and first line option for rapid acting insulin.
  • Haloperidol 500 microgram tablets to be DNP (criterion 2)
  • Berotralstat for hereditary angioedema to be added to the RAG list as a RED drug
  • Casirivimab/imdevimab (Ronapreve)® to be added to formulary as a RED drug, with link to NG191

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Thursday 23rd December 2021.

Consultation: Updated High Cost Drugs Pathway for Inflammatory Bowel Disease

November 10, 2021

On behalf of the GMMMG IBD working group, we now seek comments on this draft version of the updated GM high cost drug IBD pathway. This consultation period is open until 5pm on Wednesday 22nd December 2021.

Take part in this, and other open consultations, on the consultations home page.

Consultation: actions from October meeting of CRG

October 19, 2021

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the October 2021 CRG meeting.

Actions in this consultation include:

  • Inhaled colistimethate, dornase alfa and tobramycin for cystic fibrosis in children – RED. Repatriation should not be sought until a request to do so has been received from the specialist.
  • Bimekizumab for moderate to severe plaque psoriasis – RED.
  • Link to NG191, Managing COVID-19, to be added to formulary in chapter 2

To take part in this consultation, visit the consultations page. This consultation period is open until 5pm Tuesday 30th November 2021.

Consultation: updated asthma pathway

October 4, 2021

On behalf of the GMMMG asthma working group, we now seek comments on a draft version of the updated Greater Manchester asthma management plan. This consultation period is open until 5pm Monday 15th November 2021.